BioDelivery Sciences International, Inc. (NASDAQ:BDSI) CFO Paolantonio Ernest Robert De sold 64,155 shares of BioDelivery Sciences International stock in a transaction that occurred on Friday, April 6th. The stock was sold at an average price of $2.09, for a total transaction of $134,083.95. Following the completion of the transaction, the chief financial officer now directly owns 97,731 shares in the company, valued at approximately $204,257.79. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of BDSI traded down $0.05 during mid-day trading on Friday, hitting $2.10. The company’s stock had a trading volume of 284,601 shares, compared to its average volume of 463,167. The company has a quick ratio of 1.29, a current ratio of 1.52 and a debt-to-equity ratio of 5.37. BioDelivery Sciences International, Inc. has a fifty-two week low of $1.55 and a fifty-two week high of $3.60.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Thursday, March 15th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.05). The business had revenue of $12.51 million during the quarter, compared to analyst estimates of $9.83 million. BioDelivery Sciences International had a return on equity of 22.93% and a net margin of 8.52%. research analysts anticipate that BioDelivery Sciences International, Inc. will post -0.74 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in BDSI. Northern Trust Corp increased its position in shares of BioDelivery Sciences International by 0.9% in the second quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock worth $394,000 after acquiring an additional 1,203 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in shares of BioDelivery Sciences International in the third quarter worth approximately $116,000. Wells Fargo & Company MN increased its position in shares of BioDelivery Sciences International by 138.2% in the third quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock worth $105,000 after acquiring an additional 20,599 shares in the last quarter. Royce & Associates LP purchased a new position in shares of BioDelivery Sciences International in the third quarter worth approximately $3,814,000. Finally, Krilogy Financial LLC increased its position in shares of BioDelivery Sciences International by 28.8% in the third quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock worth $395,000 after acquiring an additional 30,000 shares in the last quarter. 45.82% of the stock is currently owned by institutional investors and hedge funds.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.